Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients

Cisplatin is a widely used chemotherapy for the treatment of certain solid tumors. Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment. To date, no therapies have been approved to prevent or treat cisplatin-induced hearing...

Descripción completa

Detalles Bibliográficos
Autores principales: Viglietta, Vissia, Shi, Fuxin, Hu, Qi-Ying, Ren, Yong, Keilty, John, Wolff, Heather, McCarthy, Ryan, Kropp, Jason, Weber, Pete, Soglia, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497691/
https://www.ncbi.nlm.nih.gov/pubmed/32157599
http://dx.doi.org/10.1007/s10637-020-00918-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497691/
https://www.ncbi.nlm.nih.gov/pubmed/32157599
http://dx.doi.org/10.1007/s10637-020-00918-1

Ejemplares similares